+86-28-82633987
Product name: Iristectorin A
Synonym name:
Catalogue No.: BP4178
Cas No.: 37744-61-9
Formula: C23H24O12
Mol Weight: 492.433
Botanical Source: Belamcanda chinensis （L.）DC.
Physical Description: 射干
Type of Compound: Flavonoids
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.
The product could be supplied from milligrams to grams
Inquire for bulk scale.
For Reference Standard and R&D, Not for Human Use Directly.
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
188.5100
.1389
.1080
1.2734
.6795
.4891
Low
81.1678
4.0237
Yes
No
Yes
No
Yes
No
0.6
Yes
No
Yes
No
Iristectorin A is a natural compound isolated from the iris plant of the Iridaceae family, and has attracted significant attention in recent years due to its remarkable biological activity. As a natural compound with multiple pharmacological effects, IV lutein not only demonstrates potential against breast cancer but also exhibits good anti-inflammatory activity, involving multiple inflammation-related signaling pathways and molecular targets. Research on iris methyl glycoside in the field of natural product pharmacology helps deepen understanding of its mechanism of action and promotes its application in new drug development. This paper will systematically review the chemical structure and physicochemical properties of iris IVD, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation, and pharmacokinetic characteristics, and finally look ahead to its clinical application prospects.
The chemical name of iris is Iristectorin A, CAS number 37744-61-9. Its molecular formula is C_24H_28O_11, and its molecular weight is 492.4330. Iris IV is an isoflavone compound containing multiple hydroxyl and glycosyl groups, giving it high polarity and water solubility. Its LogP value was 0.1389, indicating low lipid solubility and good water solubility (1.2734), which has some impact on oral absorption and internal distribution. The topological pole surface area (TPSA) is 188.51 Ų. Higher pole surface area is usually associated with poorer cell membrane permeability, which may limit its ability to cross the blood-brain barrier, consistent with its low blood-brain barrier permeability characteristics. Additionally, iris glycoside did not show hERG channel inhibitory activity, indicating a low cardiotoxicity risk. The Ames test result was 0.6, indicating a low genotoxicity risk.
In the chemical structure of iris IV, the isoflavone core ring binds with multiple hydroxyl and glycosyl groups, giving it unique biological activity. The glycoside part not only improves its water solubility, but may also affect its metabolic stability and targeting in vivo.
Iris glycoside is mainly isolated from the rhizome of the Iris tectorum plant. Iris tectorum is widely distributed in East Asia and is commonly used in traditional Chinese medicine for detoxifying, anti-inflammation, and pain relief. As one of its important active ingredients, iris glycoside has been systematically studied in recent years.
During extraction, ethanol or methanol is often used as the extraction solvent, and crude extracts are obtained through reflux extraction or ultrasound-assisted extraction. Subsequently, using multi-step separation and purification techniques such as liquid-liquid separation, silica gel column chromatography, and reversed-phase high-performance liquid chromatography (RP-HPLC), high-purity iris IVoside was successfully isolated. Optimization of extraction processes mainly focuses on improving extraction efficiency and purity while maintaining the biological activity of compounds.
In addition, modern extraction technologies such as supercritical CO_2 extraction and microwave-assisted extraction have also been attempted to extract irides, aiming to improve yield and reduce solvent usage, thereby promoting large-scale production.
Pharmacological research on iris mainly focuses on its anti-breast cancer and anti-inflammatory effects. Multiple in vitro cell experiments and in vivo animal model studies have shown that IVoside has a significant inhibitory effect on breast cancer cells, inducing apoptosis, blocking the cell cycle, and inhibiting tumor cell proliferation and migration.
Iris glycoside exerts its antitumor effects by modulating various signaling pathways. Studies have shown that it can inhibit activation of the STAT3 signaling pathway in breast cancer cells, reduce the expression of proliferation-related proteins, and induce cancer cell apoptosis. Additionally, iris IV can affect cell cycle regulatory proteins, block the G2/M phase transition, and reduce tumor cell proliferation.
Intra-idiside shows multi-target regulatory capability in anti-inflammatory effects. Its targets include pro-inflammatory factors IL-6 and TNF-α, inflammatory signal transduction molecules STAT3 and NFKB1, as well as inflammatory mediator synthesizers PTGS1 (COX-1), PTGS2 (COX-2), and NOS2 (induced nitric oxide synthase). Iris IVoside can significantly inhibit the expression and activity of these factors, reducing inflammatory responses.
Additionally, iris IV also modulates inflammation-related ion channels TRPV1 and TRPA1, possibly alleviating neuroinflammation and pain by controlling calcium influx. CASP1 (caspase-1), as a key activator of inflammasomes, has an inhibitory effect of iris IVoside, suggesting its potential value in regulating pyroptosis and inflammatory responses.
The multi-target mechanism of iris glycoside is an important basis for its pharmacological activity. Its main mechanisms of action include:
Inhibition of pro-inflammatory cytokine expression: Iris significantly reduces secretion of IL-6 and TNF-α, alleviates the inflammatory microenvironment, and blocks the spread of inflammatory signals.
Blocking the STAT3/NF-κB signaling pathway: STAT3 and NF-κB are key transcription factors regulating inflammation and tumor cell survival. Iris glycoside inhibits activation of these two pathways, reduces the expression of pro-inflammatory and anti-apoptotic genes, and promotes tumor cell apoptosis and inflammation relief.
Inhibiting inflammatory enzyme activity:P TGS1 and PTGS2 are key enzymes in prostaglandin synthesis and are involved in inflammatory responses and pain transmission. Iris IV reduces prostaglandin production by inhibiting the activity of these two enzymes, exerting anti-inflammatory and analgesic effects.
Regulation of ion channels: TRPV1 and TRPA1 play important roles in inflammation and pain signaling. Iris regulates these two channels, helping to alleviate neuroinflammation and related pain symptoms.
Inhibition of CASP1 activity: CASP1 mediates the activation of inflammasomes, promoting the maturation and release of the pro-inflammatory cytokine IL-1β. Iris inhibits CASP1, which may reduce inflammatory responses and pyroptosis.
In summary, iridesinoside demonstrates good anti-inflammatory and antitumor activity through multi-target and multi-pathway coordinated regulation, possessing high pharmacological value.
The druggability evaluation of iris showed that it has certain development potential. Its molecular weight is 492.4330, slightly above the Lipinski standard recommended below 500, but still close to a reasonable range. A LogP value of 0.1389 indicates strong hydrophilicity, which is beneficial for dissolution and distribution in the body, but may limit cell membrane penetration, especially the low permeability of the blood-brain barrier, suggesting limited application in central nervous system diseases.
TPSA up to 188.51 Ų is usually associated with poor oral bioavailability, but for drugs targeting peripheral tissues, appropriate polarity helps improve selectivity and reduce nonspecific toxicity.
Iris IV did not show hERG channel inhibition, reducing the risk of cardiotoxicity. The Ames test result was 0.6, indicating a low genotoxicity risk and good safety.
Currently, pharmacokinetic research on iris is limited. Preliminary data suggest that oral absorption may be limited, metabolism in the body mainly occurs through hepatic enzyme systems, and the activity and toxicity of metabolites require further study. In the future, structural modification or drug carrier systems will be needed to improve their bioavailability and pharmacokinetic properties.
As a natural compound with significant anti-breast cancer and anti-inflammatory activities, IV glycoside has broad clinical application prospects. Its multi-target regulatory mechanisms offer new ideas for the treatment of complex diseases, especially in tumor microenvironment regulation and chronic inflammatory disease management.
Future research should focus on the following directions:
In-depth pharmacokinetics and safety evaluation: Systematic study of the absorption, distribution, metabolism, and excretion characteristics of IV iris to clarify its in vivo behavior and provide a basis for clinical formulation design.
Structural optimization and drug design: Enhancing membrane permeability and oral bioavailability through chemical modification, or developing nanocarrier systems to improve drug delivery efficiency.
Molecular biology research on multi-target mechanisms: Using techniques such as genomics and proteomics to reveal the intracellular network of iris and uncover potential synergistic targets.
Preclinical and clinical research: Conduct systematic animal model validation and early clinical trials to evaluate efficacy and safety, and promote clinical translation.
Combination Therapy Strategies: Explore the combined use of iris IV with existing anticancer or anti-inflammatory drugs, and assess its potential for enhanced efficacy and reduced toxicity.
In summary, as a natural product with good pharmacological activity and safety, IV IV has the potential to become a novel anti-cancer and anti-inflammatory drug worthy of further research and development.
As an important active ingredient in Iris tectorum, iris IV glycoside demonstrates significant anti-breast cancer and anti-inflammatory activities due to its unique chemical structure and multi-target pharmacological effects. Its excellent safety and druggability parameters lay the foundation for subsequent drug development. In the future, systematic pharmacokinetic studies, structural optimization, and preclinical validation are expected to promote iris to become a novel drug for treating breast cancer and inflammation-related diseases. The continuous development of natural product pharmacology will provide strong support for in-depth research and clinical application of irideride, promoting the widespread use of natural products in modern medicine.
Shenshuai
Wenjing
Hedandan
